Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B.
LLY
· Healthcare · Drug Manufacturers - General
· Market cap $887.63B
LLY is 74% below fair value and in accumulation zone. Consider adding to your position.
QuantHub Research: Investment Thesis
Scaling Phase
Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B. The company guided $80-83B for 2026, well above prior Street consensus, and launched Foundayo (oral GLP-1, FDA approved April 2026) with $1.5B pre-built inventory. At $939 the stock trades at 14.8x P/S, right at its 5-year median, and 27.4x forward P/E on $34.25 midpoint 2026 non-GAAP EPS guidance. Our blended fair value of $1,607 implies 71% upside, supported by a $100B+ addressable obesity market, 60%+ U.S. incretin share, a pipeline including retatrutide (triple-agonist, Phase 3 data H2 2026), and operating leverage driving margins toward 50%. The 13% YTD drawdown on tariff fears, MFN pricing concerns, and Novo Nordisk cross-trial noise creates an attractive entry point for a generational pharma franchise.
LLY trades at 14.8x P/S, exactly at its 5-year median of 14.8x, placing it in the fair valuation regime. Trailing P/E of 46.8x is well below the 5-year median of 55.7x, and forward P/E of 27.4x on $34.25 midpoint 2026 EPS guidance is reasonable for a company growing revenue 25%+. The stock is 17% below its 52-week high of $1,134 following a 13% YTD drawdown driven by tariff concerns, MFN pricing fears, Novo Nordisk cross-trial data on oral Wegovy, and broader healthcare sector rotation. The market is discounting meaningful pricing regulation risk that may not materialize at the magnitude feared, while ignoring the Foundayo launch catalyst and $80-83B 2026 revenue guidance that beat Street estimates.
12–18 Month Outlook
Over the next 18 months, Eli Lilly should deliver $80-83B in 2026 revenue (guided) and begin generating meaningful revenue from Foundayo (oral GLP-1, approved April 2026). Key milestones include Q1 2026 earnings on April 30, retatrutide Phase 3 readouts in H2 2026, continued international Mounjaro/Zepbound launches, and manufacturing capacity ramps at new facilities. The primary risk is U.S. drug pricing policy (IRA negotiations, potential MFN and TrumpRx.gov caps), which could compress GLP-1 margins. If policy risk proves manageable and execution continues, the stock should re-rate toward $1,200-1,500 as 2027 estimates get built on $95-105B+ revenue. Downside risk to $750-850 if severe pricing regulation materializes or GLP-1 demand plateaus unexpectedly. Novo Nordisk oral Wegovy cross-trial data adds competitive noise but lacks the rigor of head-to-head trials, and Lillys manufacturing scale advantage and first-mover oral position should sustain share leadership.
Bull vs Bear
Bull Case
GLP-1 franchise (Mounjaro + Zepbound) grew to $36.5B in 2025 with 60%+ U.S. incretin market share, and the anti-obesity medication market is projected to exceed $100B by 2030, with current penetration still in the low single digits.
2026 revenue guidance of $80-83B (23-27% growth) beat Street consensus, and Q4 2025 earnings showed revenue of $19.3B (43% YoY growth) with EPS of $7.54 vs $6.91 consensus, demonstrating sustained execution.
FDA approved oral GLP-1 Foundayo (orforglipron) on April 1, 2026, with $1.5B pre-built inventory ensuring smooth launch. This opens a massive new patient population who prefer pills over injections, potentially doubling the addressable market.
Pipeline depth is exceptional: retatrutide (triple-agonist, Phase 3 data expected H2 2026 with up to 24% weight loss in Phase 2), Verzenio in early breast cancer at $6B+ run-rate, Kisunla in Alzheimers, Omvoh in IBD, and 10+ late-stage assets.
Operating margins expanded to 45.6% in 2025 from 31.6% in 2023, demonstrating powerful operating leverage as GLP-1 volumes scale ahead of fixed costs, with further expansion expected as manufacturing capacity utilization rises.
Bear Case
Novo Nordisk published cross-trial data in early April 2026 claiming superior oral Wegovy weight loss vs Foundayo, which could influence prescriber behavior and complicate Lillys first-mover oral GLP-1 advantage.
Pricing headwinds are real and intensifying: Q4 2025 realized prices fell 5% YoY, IRA cut Jardiance Medicare prices effective January 2026, and potential MFN pricing and TrumpRx.gov caps at $350 per month could compress GLP-1 margins significantly.
Massive capex cycle ($7.8B in 2025, $8.4B in 2024) is maturing but still suppresses FCF to just $9B on $65B revenue, creating execution risk at new manufacturing megafabs and limiting near-term capital return capacity.
At 46.8x trailing P/E, any growth deceleration below 20% or quarterly disappointment could trigger significant multiple contraction, as demonstrated by the 23% drawdown from $1,134 to $878 in Q1 2026 on policy fears alone.
GLP-1 competition is intensifying from Novo Nordisk (oral Wegovy, CagriSema), Amgen (MariTide monthly injection in Phase 3), Viking Therapeutics (VK2735), and generic/biosimilar entrants expected post-2030, potentially fragmenting the current duopoly into five or more players by 2028.
Leadership & Competitive Position
David A. Ricks
Tenure9.3 yrs
Insider ownership0.3%
Beats guidance85% of qtrs
Capital allocationExcellent
Ricks has been CEO since January 2017 and Chair since June 2017, with 30+ years at Lilly since joining in 1996. Under his leadership, Lilly navigated the Cialis/Humalog patent cliff and repositioned around GLP-1s, oncology, and neuroscience. Key acquisitions include Loxo Oncology (2019, $8B) and strategic licensing deals. Revenue grew from $28.3B (2021) to $65.2B (2025), a 23% CAGR. He authorized $20B+ in manufacturing investment for tirzepatide capacity and publicly opposed proposed pharmaceutical tariffs and MFN pricing, warning they would undermine U.S. manufacturing leadership. 2024 compensation was $29.2M. Capital allocation is exceptional given the simultaneous execution of massive capex buildout, strategic M&A, $4.1B in share buybacks (2025), and dividend growth.
Competitive Moat
widening
intangible assetsswitching costsscale economies
Lilly holds 60%+ U.S. incretin market share as of Q4 2025, up from roughly 40% in early 2024. The GLP-1 moat continues to widen vs Novo Nordisk driven by three factors: (1) superior tirzepatide efficacy data (dual GIP/GLP-1 mechanism), (2) manufacturing scale advantage with $20B+ invested in new megafabs, and (3) first-mover advantage in oral GLP-1 with Foundayo FDA approval. Novo Nordisk cited Lilly competition as a factor in its own negative 2026 guidance of minus 5% to minus 13% sales growth. In oncology, Verzenio is the leading CDK4/6 inhibitor for early breast cancer with $6B+ run-rate. Cardiometabolic Health represents 74.9% of total revenue. Patent protection on tirzepatide extends through the early 2030s.
Competitors: NVO, AMGN, AZN, PFE, VKTX
Disruption: Medium
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
46.76x
65.65x
55.66x
46.76x
100.04x
P/S
14.81x
15.36x
14.81x
9.3x
15.44x
P/FCF
107.56x
107.56x
75.56x
48.89x
1678.17x
P/S at 14.8x vs 5yr median 14.8x, sitting right between p25 of 12.2x and p75 of 15.4x, placing it squarely in the fair valuation band. P/E at 46.8x is at the low end of its 5-year range (46.8-100.0x). The stock has repriced lower from the cheap reading last update as P/S moved up slightly from 13.9x to 14.8x on the price decline being offset by a lower share count in the ratio calculation.
Scenario Matrix (5-year)
Conservative / Conservative Multiple (10.0x PS)
$1460
+9.2% / yr
Conservative / Median Multiple (12.0x PS)
$1752
+13.3% / yr
Conservative / Optimistic Multiple (15.0x PS)
$2190
+18.4% / yr
Base / Conservative Multiple (10.0x PS)
$1806
+14.0% / yr
Base / Median Multiple (12.0x PS)
$2167
+18.2% / yr
Base / Optimistic Multiple (15.0x PS)
$2709
+23.6% / yr
Optimistic / Conservative Multiple (10.0x PS)
$2215
+18.7% / yr
Optimistic / Median Multiple (12.0x PS)
$2658
+23.1% / yr
Optimistic / Optimistic Multiple (15.0x PS)
$3323
+28.8% / yr
DCF: $815
· 0.1 discount rate
· x terminal multiple
· Blended methodology — DCF models cash flows; fair value blends DCF with comparables multiples.
Key Metrics
Revenue Growth
44.7%
Gross Margin
83.8%
ROE
77.8%
FCF Yield
0.93%
Debt/Equity
1.6x
P/E Forward
27.4x
P/E Trailing
46.76x
P/S
14.81x
P/FCF
107.56x
EV/EBITDA
35.81x
Op. Margin
45.6%
Dividend Yield
0.56%
Price Context
Trend
Above 200sma
RSI (14-day)
57.8 neutral
Support
$878
Resistance
$1008
Catalysts
2026-04-30
Q1 2026 Earnings Report
First quarter to include Foundayo launch data and updated 2026 guidance. Consensus expects continued 25%+ revenue growth. Beat-and-raise would validate $80-83B guide and likely push stock above 50-SMA resistance.
high impact
2026-Q2
Foundayo (oral GLP-1) Commercial Launch Ramp
FDA approved April 1, 2026 with $1.5B pre-built inventory. Prescription volume trajectory in first 90 days will signal oral GLP-1 market acceptance. Strong uptake could add $3-5B annualized revenue by year-end.
high impact
2026-H2
Retatrutide Phase 3 Data Readouts
Triple-agonist (GLP-1/GIP/glucagon) showed up to 24% weight loss in Phase 2. Phase 3 data expected H2 2026. Positive results would establish next-generation obesity franchise worth $15B+ peak sales and further widen the moat vs competitors.
high impact
2026
U.S. Drug Pricing Policy Clarity
Resolution on MFN pricing, TrumpRx.gov $350/month cap proposals, and IRA Medicare negotiation scope. Policy overhang is the single largest source of valuation uncertainty. CEO Ricks has publicly opposed tariffs and MFN, arguing they undermine U.S. manufacturing investment.
high impact
2026-2027
Manufacturing Capacity Expansion
New tirzepatide manufacturing megafabs coming online through 2027 after $20B+ cumulative investment. Capacity scaling is essential to meeting $80-83B revenue guide and supporting international expansion without supply shortages.
medium impact
2026
International Zepbound Launches
Zepbound approved in EU and expanding into Asia-Pacific markets. International obesity revenue currently a small fraction of U.S. numbers, representing multi-billion dollar incremental opportunity as manufacturing capacity unlocks.
medium impact
Risks
Drug pricing regulation
high
IRA Medicare negotiations already cut Jardiance prices effective January 2026. Potential MFN pricing and TrumpRx.gov $350/month caps could significantly compress GLP-1 margins. Q4 2025 realized prices fell 5% YoY. Tirzepatide is currently priced at approximately $1,000/month list; forced reductions to $350 would devastate unit economics. CEO Ricks has publicly opposed tariffs and MFN policy, warning of undermined U.S. manufacturing leadership, but political resolution remains uncertain.
GLP-1 competitive intensity
high
Novo Nordisk published cross-trial data in April 2026 claiming oral Wegovy superiority vs Foundayo, and cited Lilly competition as a factor in its own negative 2026 guidance (minus 5% to minus 13% sales growth). Amgen MariTide (monthly injection) advancing in Phase 3. Viking Therapeutics VK2735 progressing. Generic/biosimilar tirzepatide threat post-2030. Market could fragment from current duopoly to 5+ players by 2028.
Manufacturing execution risk
medium
LLY invested $7.8B in capex in 2025 and $8.4B in 2024, building multiple new manufacturing megafabs for tirzepatide. Any disruption, quality issue, or delay at these facilities could cause material revenue shortfalls. Days of inventory outstanding expanded to 475 days in 2025, reflecting the massive pre-build for Foundayo launch but also tying up significant working capital.
Valuation compression
medium
At 46.8x trailing P/E and 14.8x P/S, any growth deceleration below 20% or disappointing quarterly results could trigger meaningful multiple compression. The stock already fell from $1,134 to $878 (23% drawdown) in Q1 2026 on policy fears alone, demonstrating the sensitivity to sentiment shifts.
Patent and IP risk
low
Core tirzepatide patents extend into early 2030s, but biosimilar challenges could emerge earlier. China and Southeast Asia expansion exposes IP to jurisdictions with weaker enforcement. Ongoing GLP-1 gastroparesis litigation creates tail risk but is not expected to have material financial impact.
Growth Engines
Mounjaro (tirzepatide for diabetes)scaling
Type 2 diabetes market is $60B+ globally. Mounjaro reached $22.97B in 2025 (99% YoY growth). International expansion ongoing with EU and Asia-Pacific launches ramping.
Zepbound (tirzepatide for obesity)early_scaling
Anti-obesity medication market projected to reach $100B+ by 2030 with current penetration in the low single digits. Zepbound hit $13.54B in 2025 (175% YoY growth) in its second full year on market.
Foundayo (orforglipron, oral GLP-1)launch
FDA approved April 1, 2026. Oral formulation unlocks patients who refuse injections, potentially 50%+ of addressable obesity/diabetes population. $1.5B pre-built inventory for launch. Could generate $5B+ in first full year if uptake matches initial expectations.
Oncology (Verzenio, Jaypirca, Retevmo)maturing
Verzenio at $6B+ annual run-rate in breast cancer, contributing to cumulative oncology revenue of $9.3B TTM through Q3 2025. Jaypirca in MCL and Retevmo in RET+ cancers provide diversification.
Omvoh for IBD, Kisunla (donanemab) for Alzheimers, Ebglyss for atopic dermatitis. Combined TAM exceeds $50B. Immunology revenue reached $5.0B TTM through Q3 2025. Early commercial phase with significant ramp potential.
Phase 3 for obesity with potential best-in-class efficacy (up to 24% weight loss in Phase 2). Phase 3 data expected H2 2026. Could launch late 2027-2028 if trials succeed, targeting the $100B+ obesity market with an estimated $15B+ peak sales potential.
FDA approves Foundayo (orforglipron), Lillys oral GLP-1 agonist
First-to-market oral GLP-1 for obesity and diabetes. Lilly pre-built $1.5B inventory to ensure smooth launch without shortages. Opens massive new patient population preferring pills over injections. Positions Lilly as the most commercially significant product launch in years.
2026-04-04
Novo Nordisk publishes cross-trial data claiming oral Wegovy superiority vs Foundayo
Competitive salvo from Novo Nordisk days after Foundayo FDA approval. Methodological limitations of cross-trial comparisons may limit clinical impact, but created negative sentiment and prescriber uncertainty. Lacks the rigor of head-to-head trials.
Mounjaro plus Zepbound combined $11.7B in Q4, ahead of $10.6B consensus. Full-year 2025 revenue $65.2B (45% growth). 2026 guidance of $80-83B beat $77.5B Street estimate and triggered a 10% stock surge post-announcement.
2026-Q1
LLY stock declines 13% YTD on policy fears, tariff concerns, and Novo cross-trial data
Stock fell from $1,092 post-earnings to $878 trough in late March, then bounced to $939 by April 10. Decline driven by MFN pricing fears, proposed pharmaceutical tariffs, healthcare sector rotation, and competitive noise from Novo Nordisk.
2026-01-01
IRA-negotiated Jardiance price cuts take effect for Medicare patients
First direct revenue impact from IRA drug pricing provisions. Establishes precedent for future Medicare negotiations that could eventually include GLP-1 drugs. Manageable near-term financial impact but important signal for policy trajectory.
Original research. Not scraped from Wall Street.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.